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OPTIMIZING RIBOFLAVIN/ ULTRAVIOLET-A CORNEAL COLLAGEN 
CROSS-LINKING FOR THE TREATMENT OF PROGRESSIVE 
KERATOCONUS 
 
DANIEL J. SYLVESTRE 
 
ABSTRACT 
 
 Patients with keratoconus exhibit a biomechanically weakened cornea 
which loses its proper shape and thereby loses its refractive power. It is usually 
progressive, beginning with poor visual acuity and eventually necessitating 
corneal transplant. The cause is likely multifactorial, but involves the weakening 
of the collagen structure of the corneal stroma, resulting in characteristic thinning 
and conical distortion. Collagen cross-linking is the first treatment to demonstrate 
efficacy in halting the progression of the disease. UVA radiation is used to 
activate riboflavin and photochemically induce cross-linking reactions among 
collagen and proteoglycans within the stroma, thereby stiffening and 
strengthening the tissue, and preventing further loss of shape. The current 
standard treatment, which gained FDA approval less than one year ago, has 
proven to be efficacious, but has been modified very little since pioneering 
experiments. Optimization aims to maximize clinical effect while maintaining 
safety and reducing total treatment time. Major procedural modifications involve 
 v 
 
increasing light intensity over a reduced exposure duration, and varying the 
method of delivering riboflavin to the stroma. Theoretical modeling, informed by 
and scaled to experimental results, has the potential to predict clinical effect as a 
function of treatment parameters, enabling tailoring of individual treatments to the 
specific needs of each patient.  
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INTRODUCTION 
 
The cornea is a transparent structure forming the anterior portion of the 
eye. It is simultaneously responsible for protecting the eye from mechanical and 
infectious insult and, together with the tear film, providing roughly 74% of the 
average eye’s 58.6 diopter total refractive power. 1 The specific organization of 
the its cellular and extracellular components impart the cornea’s mechanical 
integrity, and abnormalities therein can lead to distortion of the cornea’s shape, 
resulting in failure to properly refract light for optimal visual acuity (refractive 
error).  
 
Keratoconus is a relatively common degenerative condition marked by 
progressive thinning of the cornea (ectasia) which causes it to bulge outward in a 
conical shape. The resulting decline in visual acuity may be compounded by 
scarring and other complications. It typically presents in early adulthood, and is 
believed to be the result of a combination of genetic and environmental factors. 
Mild cases may only cause poor visual acuity and astigmatism (a deviation from 
spherical curvature, which prevents light rays from meeting at a common focus), 
correctable with glasses or contact lenses. More severe cases eventually require 
corneal transplant (keratoplasty). Keratoconus is the single most common reason 
for keratoplasty in the developed world. Research has demonstrated that 
progression of keratoconus can be halted by photodynamic therapy using 
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ultraviolet light and riboflavin as a photosensitizer to induce corneal collagen 
cross-linking. 
 
This introduction will focus on the structural organization of the cornea as 
it pertains to its mechanical integrity, factors contributing to the loss of said 
integrity in keratoconus, and the most commonly employed treatments available 
prior to the FDA approval of Riboflavin/UV-A induced corneal collagen cross-
linking (CXL). The following discussion will compare the current protocol for CXL 
(Avedro’s KXL system), with a few proposed procedural modifications which 
hope to optimize this promising but still nascent treatment. 
 
Anatomy of the Healthy Cornea 
 The average adult cornea’s diameter is approximately 10.5 mm vertically 
and 11.5 mm horizontally. The average radius of curvature of the anterior surface 
of the central cornea is 7.8 mm. It is about 0.5 mm thick at the central apex, and 
gradually thickens to about 0.7 mm toward the periphery where it is limited by the 
limbus, the border between the cornea and the sclera (the white of the eye). The 
cornea is both avascular and devoid of lymphatic drainage, and relies on 
diffusion of nutrients from the aqueous humor - glucose, amino acids, ascorbic 
acid, other vitamins, and lactic acid – and oxygen indirectly from the air via the 
tear film. Despite being avascular, the cornea is extremely sensitive, with a 
density of nerve endings approximately 300 times that found in skin. Innervation 
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originates from the nasociliary nerve of the ophthalmic division of the trigeminal 
nerve. 1 In the region of the limbus, the corneal epithelium becomes continuous 
with that of the bulbar conjunctiva, a thin mucous membrane which covers the 
anterior part of the sclera. The sclera provides the attachment points for the recti 
muscles which move the eye. It is at these insertions that the anterior ciliary 
arteries, which stem from the ophthalmic artery and provide blood supply to the 
anterior segment, emerge. As shown in Figure 1, there are five recognized 
corneal layers: epithelium, Bowman’s layer, stroma, Descemet’s membrane, and 
endothelium. Posterior to the corneal endothelium is the anterior chamber, the 
fluid-filled space between the cornea and the iris (the colored portion of the eye 
surrounding the pupil).2  
 4 
 
 
Figure 1: Light micrograph of the human cornea. 3 
 
The corneal epithelium is composed of extremely uniform stratified 
squamous non-keratinized cells 4-6 layers totaling approximately 43 μm in 
thickness. 4 It consists three different types of epithelial cells: superficial, wing, 
and basal cells. With an average cell lifespan of 7-10 days, deeper basal cells 
constantly divide and move apically to replace desquamating superficial cells, 
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resulting in a complete turnover of the epithelium every week. 5 Cells in the 
outermost layer maintain complexes of tight junctions between them to prohibit 
tears or foreign chemicals from entering the intercellular spaces. Zonulae 
adherens and desmosomes are present in all layers of the corneal epithelium, 
but gap junctions which allow small molecules to pass between neighboring cells 
are only found in the wing and basal cell layers. Superficial cells project 
numerous apical microvilli to increase the cell surface area for contact with the 
tear film. The glycocalyx of these cells provide anchorage for the tear film via 
association with its inner mucinous layer, which functions to improve the wetting 
properties of the tears and is produced by goblet cells in the conjunctival 
epithelium. The middle aqueous layer of the tear film is produced by lacrimal 
glands around the eye. It allows for even spreading of the tear film over the 
cornea with each blink, and contains electrolytes, proteins, lysozyme, 
immunoglobulins, glucose, and dissolved oxygen from the atmosphere, all 
necessary for proper nourishment of the cornea.  The outermost lipid layer is 
produced by the meibomian glands (modified sebaceous glands) of the eyelid 
margins. It helps maintain the column of tears between the upper and lower lids, 
and slows the rate of evaporation of water from the corneal surface. 2 Thus, a 
healthy tear film allows for a smooth surface for the passage of light, protects it 
from microbial, chemical, or foreign body assault, and brings nourishment to the 
avascular cornea including immunological and growth factors which are critical to 
epithelial proliferation and repair. 6 If the epithelium is damaged, epithelial stem 
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cells localized to the basal layer of the limbus migrate to the central cornea, 
differentiating into transient amplifying cells (capable of multiple but limited 
division), and basal cells. 7 The early nonmitotic coverage phase begins within 
minutes and can proceed at a remarkable rate, upwards of 70 μm per hour. 8 24-
30 hours later, the basal cells, transient amplifying cells, and limbal stem cells 
begin mitosis to replenish the cell population. Type IV collagen and laminin 
secreted by the basal cells are the major components of the epithelial basement 
membrane, which separates the epithelium from the underlying Bowman’s layer, 
with type VII collagen anchoring fibrils passing between them to provide 
adhesion of basal cells to the basement membrane and to the stroma. Damaging 
the basement membrane can prolong epithelial healing to weeks as opposed to 
days. 1,9 
 
Technically not a membrane, Bowman’s layer is the anterior-most portion 
of acellular stroma, made up of collagen fibrils (primarily types I and III) and 
proteoglycans about 17 μm thick. Its precise role is still unclear, although it may 
help the cornea maintain its shape, or provide a simple barrier function. It does 
not regenerate, and its disruption may lead to scar formation. 1,4 
  
The stroma constitutes the bulk of corneal tissue, accounting for nearly 
86% of its thickness. 4 Keratocytes residing mostly in the anterior corneal stroma 
are the major cell type and are responsible for secreting the collagen, 
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proteoglycans, and matrix metalloproteases (MMPs) which constitute the stromal 
extracellular space. Collagen accounts for 70% of the total dry weight of the 
cornea. Corneal collagen forms fibrils with a uniform diameter of approximately 
30 nm, which are arranged into larger fibers or lamellae 1-2 μm thick and 
anywhere from 10 to 200 μm in length, allowing them to traverse the entire 
cornea from limbus to limbus. 10 The distances between fibers is identical 
(approximately 42 nm) and their direction in any given lamella is the same, but 
oriented at a right angle to those of adjacent lamellae. The precise organization 
of these fibers is the main determinant of corneal transparency, and provides the 
structural foundation which dictates the cornea’s overall shape and 
biomechanical strength. 1,11  A detailed description of the organization and 
properties of stromal collagen will be presented in the next section.  
Descemet’s membrane is the basement membrane of the corneal 
endothelium. It is constantly secreted by the endothelial cells since before birth 
and can accumulate up to 10 μm thick with age. It is composed of type VIII 
collagen and its health is important for the proper exchange of nutrients between 
the stroma and the anterior chamber. 12 
  
The corneal endothelium is composed of a single layer of squamous non-
keratinized cells having a honeycomb-like mosaic appearance when viewed with 
specular microscopy. It is approximately 4 μm thick in adulthood. These cells 
have a high density of ion transport pumps which maintain an osmotic gradient 
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for fluid flow posteriorly through and out of the corneal stroma, maintaining the 
stroma in the relatively deturgesced state (78% water content) necessary for its 
transparency. Cell density of the corneal endothelium is around 3500 cells/ mm2 
at birth and decreases with age at a rate of approximately 0.6% per year. 
Because of the critical role these cells play in maintaining the water balance of 
the cornea, a reduction in cell count to below 500 cells/ mm2 due to age, trauma, 
inflammation, and other disease processes can result in corneal edema. 
Remaining cells do have the capacity to “stretch” to fill in the space left by 
degeneration; however, as this occurs, the remaining cells grow in size 
(polymegathism) and lose their archetypal hexagonal shape (pleomorphism), 
both of which are histological indications which correlate to a reduced ability of 
the endothelium to prevent said edema. 9 These histological correlates allow for 
the assessment of the health of the endothelium, and thus of the cornea, by 
specular microscopy.    
  
Collagen of the Corneal Stroma 
Collagen Formation 
Collagens are trimeric proteins having at least one collagenous or COL 
domains as well as non-collagenous or NC domains, the number and structure of 
each depending on the specific collagen type. There are 28 distinct collagen 
glycoproteins encoded by at least 45 genes designated by Roman numerals (I-
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XXVIII) in chronological order of discovery. For each type, each genetically 
distinct alpha polypeptide chain is designated by Arabic numerals. This 
discussion will focus only on corneal collagens, specifically those found in the 
corneal stroma, as this is the primary locus of the effects of photodynamic cross-
linking. Figure 2 part A provides an overview illustration of the steps of collagen 
formation from polypeptide synthesis to fibril assembly.  
Collagens I, III, and V form striated fibrils. Unlike I and III, Collagen V 
retains its N-terminal domain and is involved in the regulation of fibril assembly. 
Collagen VI forms beaded filaments or networks. There are also collagens that 
do not form fibrils but are associated with other fibrils, FACITs (fibril-associated 
collagen with interrupted triple helix). Directed fibril assembly into the highly 
organized suprastructures observed in tissues such as the cornea depends on 
cell interaction with the extracellular matrix via organizing molecules such as 
fibronectin, which itself organizes into a network of fibrils via interaction with 
integrins. This fibronectin network provides binding sites for collagen fibril 
assembly. Further assembly of mature fibrils via linear and lateral growth of the 
preformed intermediates is regulated by small leucine-rich proteoglycans 
(SLRPs) and FACIT collagens. 13 
 
Fibril-forming collagens are initially secreted from cells (in the cornea, 
keratocytes) as procollagens which contain a non-collagenous C-terminal and an 
N-terminal propeptide, the presence of which prevents premature assembly of 
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collagen molecules into fibrils inside the cell. Enzymes specific to each collagen 
type process the propeptides to leave one large central triple helical domain and 
short non-collagenous end sequences termed telopeptides. For Collagen III and 
V, this processing can be incomplete, with retention of a C-telopeptide and a 
partially processed N-propeptide which function as fibrillar assembly regulators. 
13 
 
Collagen molecules are composed of three left-handed helical polypeptide 
chains within a right-handed superhelix. Initial translation produces pre-pro-
peptides which are directed into the lumen of the rough endoplasmic reticulum 
(RER) of the collagen-secreting cell. Cleavage of the N-terminal signal peptide 
produces a pro-alpha chain which, after co-translational enzymatic hydroxylation 
(of prolyl and lysyl residues) and glycosylation of hydroxylysyl residues, trimerize. 
The hydroxylating enzymes, located either within the lumen or on the inside of 
the RER, require Fe2+, 2-oxoglutarate, molecular oxygen, and ascorbate as co-
factors. Glycosylation of hydroxylysyl residues in collagen requires two enzymes: 
hydroxylysyl galactosyltransferase, and galactosylhydroxylysyl 
glucosyltransferase. The extent of glycosylation is collagen type specific and only 
occurs on non-triple helix substrates (alpha chains). After synthesis is completed, 
the globular domains fold, stabilized by disulfide bonds, and helix formation 
begins. Three left-handed coiled alpha chains will supercoil into a right-handed 
triple helix which is stabilized by inter-chain hydrogen bonds to form the pro-
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collagen molecule which exits the cell. Steric hindrance dictates that only glycine 
can fit in the central position; thus, the triple helical domains have a repeating 
(Gly-X-Y) pattern, with the X and Y positions usually occupied by proline or lysine 
residues. Hydroxylation creates two polypeptides unique to collagen, 
hydroxyproline (the most characteristic amino acid of collagens, important for 
helix stability), and hydroxylysine (important for down-stream glycosylation). The 
extent of post-translational glycosylation affects the circumference of the COL 
triple helical domains and therefore proper fibril assembly. 13 
 
Once they leave the cell via the Golgi, propeptides are cleaved by 
proteinases and triple helices self-assemble into a staggered axial array to form 
microfibrils consisting of five molecules and 4-8 nanometers wide. 14 Different 
combinations of polypeptide chains (alpha chains) assemble to create different 
types of collagen, several of which are present in the human cornea. Microfibrils 
then coil together to form the 30-nm diameter collagen fibril seen in the electron 
microscope. During fibrillogenesis, parallel collagen molecules are aligned with a 
small shift to the next (about 25% the length of the collagen molecule) resulting in 
the classical “quarter-stagger” configuration and the characteristic banded 
appearance of collagen fibrils under electron microscopy (Figure 2 part B). 
Because the microfibrils in corneal collagen are tilted about 15 degrees in 
respect to the fibril long axis, the usual 67 nm axial periodicity, termed the D-
period, is reduced to closer to 65 nm and results in a fibril which is narrower than 
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those found in non-transparent collagen elsewhere in the body such as tendon or 
sclera which have a more parallel arrangement of microfibrils within them. 15 
 
 
Figure 2: Collagen synthesis (A), and characteristic banded pattern of collagen 
with electron microscopy (B). 16 
 
Microfibrils are stabilized by the lysyl oxidase (LOX) enzyme catalyzed 
intermolecular covalent cross-linking between specific amino acids, mostly 
modified lysine residues. 17 One amino group within the nonhelical telopeptide is 
oxidized to form a reactive aldehyde which then bonds to the carbonyl group of 
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the opposing lysyl residue to produce either an aldimine or keto-imine bond (see 
Figure 3 below). These bonds can be stabilized by reduction with borohydride to 
enable isolation and quantification. The type of cross-link is dictated by whether 
the lysyl residue is hydroxylated, the chance of which is in turn dictated by the 
level of lysyl hydroxylase in the tissue. Thus, the enzyme that hydroxylates 
lysine, the long form of lysyl hydroxylase-2, 18 functions as the primary control for 
the positional pattern of lysyl oxidase-mediated collagen cross-linking. The 
importance of lysyl oxidase has been demonstrated by its total inhibition in rats 
treated with β-aminopropionitrile, preventing cross-link formation and resulting in 
collagen (of aortic tissue in the cited example) lacking tensile strength.19 
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Figure 3: Collagen cross-linking mediated by lysyl oxidase. 20 
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The relative proportions of link types are also age-dependent, there being 
a high proportion of the keto-imine in embryonic corneal collagen and a 
changeover to only the aldimine in the postnatal cornea. Given that for any given 
tissue the type of cross-link will be consistent despite there being different types 
of collagen present, cross-linking appears to be tissue specific rather than 
specific to collagen type. 21 Although all cross-linking reactions after aldehyde 
formation occur spontaneously, the highly ordered three-dimensional 
arrangement of collagen molecules within the assembling microfibril, governed 
by hydrophobic and electrostatic interactions, facilitates reactions between 
specific amino acid residues – aldehydes within the C- and N-terminal 
telopeptides react with lysine or hydroxylysine residues at position 87 and 930 
respectively. In vivo, the reducible aldimine linkages further react with helical 
histidine to form the more stable non-reducible HHL (histidine-
hydroxylysinonorleucine), cross-links, further stabilizing the fibril network against 
mechanical stresses. 18,22  
 
In contrast to enzymatic cross-linking and disulfide bonding, which are 
normal cross-linking processes tightly controlled by the body for collagen 
synthesis and tissue organization, non-enzymatic cross-links accumulate in an 
uncontrolled manner, often having deleterious effects. One such mechanism 
involves glycation and the products of such reactions, AGEs (advanced glycation 
end-products). AGEs form as a function of age via the Maillard reaction between 
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amino acids (especially lysine and proline) and reducing sugars such as glucose. 
23 Instead of forming cross-links between telopeptides, these reactions can link 
helical domains, leading to tissue stiffness and an increased resistance to 
enzymatic degradation, which disrupts the normal metabolic turnover of 
collagenous tissue and may lead to fibrosis. 24 However, in KC corneas, this age-
related stiffening may be beneficial to the otherwise weak stroma, perhaps 
explaining the mitigation and eventual cessation of disease progression seen in 
most patients by the fourth decade of life. 
Types of Stromal Collagens 
Collagen I is the most abundant of all collagens, found in almost all 
connective tissues, and representing the greatest proportion of collagens in any 
given tissue (bone and tendon is 99% Type I). In the cornea, it represents 75% of 
the collagenous component of the tissue. 25 The triple helix structure of the most 
common isoform of Collagen I, the type found in the cornea, has the 
heterotrimeric chain composition α1 (I)2 α2 (I), or two alpha 1 polypeptides 
twisted together with one alpha 2 polypeptide. 26 This isoform forms heterotypic 
fibrils with Collagen V, ensuring the regular organization of fibrillar lamellae as 
well as the unique thinness of each fibril which is crucial for corneal strength and 
transparency. 27 
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Collagen III is a homotrimer composed of three alpha polypeptides. It also 
associates with Collagen I in heterotypic fibers. Although it is abundant in 
interstitial tissue reticular fibers (lung, liver, dermis, spleen, blood vessels), as 
well as elastic tissues, it is weakly expressed in the normal cornea. However, its 
expression greatly increases in wound healing or inflammation, and is found 
abundantly in corneal scars. Thus it is considered a principal marker of the 
stromal matrix remodeling which occurs after corneal injury. 25,28 
 
Collagen V is relatively abundant in the cornea as compared to other 
tissues, representing roughly 17% of total collagen content. 25 Collagen V plays a 
central role in fibril assembly initiation by nucleation, and its N-terminal domain is 
responsible for regulating fibril diameter. The abundance of Collagen V in the 
cornea provides many nucleation sites for the assembly of more numerous, 
smaller-diameter Collagen I fibrils. Furthermore, reducing the amount of Collagen 
V (e.g. in genetic knockout mouse models), results in fewer fibrils with larger 
diameters and a disorganized lamellar structure, and loss of corneal 
transparency. 29,30  
 
FACITs (fibril-associated collagens with interrupted triple helices) have 
short COL domains interrupted by NC domains and an N-terminal NC domain 
which projects into the interfibrillar space. Two C-terminal domains are believed 
 18 
 
to interact with collagen I fibrils, and the N-terminal globular domains protrude 
from the fibril surface, affecting fiber suprastructures and biomechanics. 
 
 Proteoglycans are macromolecules containing a protein core with a 
variable number of glycosaminoglycans (GAGs) attached to it. Collagen fibrils 
also cross-link non-covalently via interactions with proteoglycans (PGs) and their 
associated GAGs. These interactions play a crucial role in the spacing of 
collagen fibers and their orientation, with the length of the GAG-chains dictating 
the distance between collagen fibrils (interfibrillary distance). 31 
 
The normal adult human cornea contains the following small leucine-rich 
proteoglycans (SLRPs): decorin, containing the GAGs dermatan sulphate and 
chondroitin sulphate (CS/DS), and lumican, keratocan, and mimecan, which 
contain keratan sulphate (KS) GAGs, the most plentiful corneal GAG. 27 Heparan 
sulfate proteoglycans are minor components of the cornea and are mainly 
synthesized by the epithelial cells. 25 SLRP protein cores are synthesized in the 
rough endoplasmic reticulum and the GAG chains are added in the Golgi, before 
secretion into the ECM. Defective synthesis of SLRPs causes blindness in 
humans by disrupting collagen fibril organization. Genetic knockout studies in 
animals have further affirmed the importance of SLRPs. For example, deficient 
decorin expression in mice results in fragile skin and dysregulated lateral growth 
of fibrils. Keratocan knockout results in altered corneal structure, especially 
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stromal thinning. Human deficiency in keratocan is associated with cornea plana, 
a congenital condition which causes a decrease in the curvature and therefore 
refractive power of the cornea, causing symptoms ranging from simple 
farsightedness to structural malformations and progressive loss of vision in 
severe cases. 26 
 
Collagen VI is a nonfibrillar type especially abundant in the cornea. It is 
characterized by a relatively short triple helical domain and the presence of large 
globular domains, one of which is a characteristic 140 kDa glycoprotein. It is 
resistant to degradation by bacterial collagenase, contributing to the immune 
defense of the eye, and contains numerous inter-chain disulfide bridges which 
stabilize its tertiary structure. 32 It is typically a heterotrimer of the α1, α2, and α3 
chains, with the α3 chain possessing a distinct extended N terminus with an array 
of consecutive von Willebrand factor type A domains. These specialized domains 
undergo conformation change and a fraction of them dimerize in the presence of 
divalent cations. Thus, the conformational state of Collagen VI is substrate 
specific and will depend on the local charge environment in vivo, modulation of 
which may reveal or hide binding sites for the numerous other extracellular 
molecules with which it interacts. 33,34 Because of its large number of potential 
interactions, collagen VI likely serves as an integrator of the various components 
of extracellular space with resident cells, a cooperation which is critical to the 
organized deposition/ assembly of collagen in the ECM.  
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Collagen VI’s supramolecular assembly is different from that of fibrous 
collagens discussed above. Monomers dimerize in lateral, anti-parallel fashion 
with C-terminal domains interacting with helical domains and stabilized by 
disulfide bonds. The resulting overlap creates a 30 nm “stagger” of a central 75 
nm supercoiled helical domain flanked by the regions of C then N-globular 
domains. Still within the cell, dimers align into tetramers which are then secreted 
and associate end-to-end to form beaded filaments (which then associate 
laterally to form broad banded fibrils) having a periodicity of approximately 100 
nm. Alternatively, tetramers may assemble non-linearly into hexagonal lattices, 
with the N-termini providing points of interaction with other ECM components. 13 
Which suprastructure the tetramers assume is also affected by the imposition of 
other integrated molecules. For example, SLRPs substituted with dermatan 
sulfate (DS) chains have been shown to induce hexagonal lattice formation. 35 
Within the cornea, the hexagonal lattice arrangement of Collagen I fibers is 
critical for the transparency of this special tissue. 27 
 
Macroscopic Organization of Stromal Collagen 
As mentioned above, collagen of the corneal stroma is laid down within 
thin sheets called lamellae, each layer of variable dimensions but typically 1-
2 μm thick and up to 0.2 mm broad. Approximately 240 lamellae comprise the 
thickness of the central human cornea. Anterior lamellae are densely packed, 
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and highly interlaced, with most of them anchoring their ends into Bowman's 
layer. These transverse-oriented fibers insert into Bowman’s layer at relatively 
shallow angles, 95% of them within + or – 11 degrees relative to the corneal 
surface. 11 Increased randomness of angles and branching within the anterior 
stroma increases tissue stiffness, and a lack of such branching in keratoconus 
increases corneal compliance and results in a less biomechanically stable 
anterior cornea more susceptible to interlamellar slippage. 36,37 Moving 
posteriorly in the central cornea, lamellar packing density decreases, as well as 
the extent of interlacing, and the degree of hydration increases. The radial 
orientation of lamellae becomes less random, with a greater proportion arranged 
orthogonally, pointed in one of two preferred orientations, either the superior-
inferior or nasal-temporal directions (see Figure 4). This contrasts with the more 
isotropic anterior stroma. Among these posterior lamellae, orthogonal preference 
is gradually lost moving from the central cornea toward the periphery as fibrils 
adopt an orientation more tangential to the edge of the cornea, eventually 
forming a circumferential annulus at the limbus. 38–40  
 22 
 
 
Figure 4: Preferential orientation of lamellae in the posterior cornea. 41 
 
 
Being less rigid relative to the anterior cornea, the posterior stroma is 
more susceptible to edema. Swelling anywhere in the cornea is therefore 
directed posteriorly and causes a general flattening of the Descemet’s 
membrane. With the limbus providing a structural limit, a flattened Descemet’s 
membrane may crimp into folds at the periphery, creating striae visible upon 
clinical slit-lamp examination (Vogt’s striae). 9 This is a helpful diagnostic criterion 
for identifying corneal pathology including keratoconus. A prevalence of elastic 
fibers also exists in the peripheral cornea, which explains the pliability of this 
region and its ability to absorb intraocular pressure fluctuations, sparing the 
optically important central cornea from deformation. 42 Finally, so called 
“anchoring fibers” extend from the limbus to mid-stroma, gradually moving 
anteriorly before anastomosing with the isotropic anterior collagen fiber network. 
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These seem to directly connect the anterior central cornea with deeper sclera, 
further reinforcing it against mechanical distortion. 43 Thus, the macroscopic 
arrangement of lamellae is critical to the cornea’s biomechanical strength and 
shape-maintenance.  
 
Keratoconus 
Signs and Symptoms 
The primary symptom of keratoconus (KC) is progressive decline of visual 
acuity with high, often irregular, astigmatism, which eventually becomes difficult 
to correct with lenses. Signs include Fleisher’s ring - a circular deposition of iron 
in the epithelium surrounding the base of the cornea, and Vogt’s striae - fine 
vertical lines visible upon slit-lamp examination which are produced by 
compression of Descemet’s membrane. Thinning of the central cornea may be 
revealed by high-magnification slit-lamp examination, or by ultrasound 
pachymetry. With further progression, the cornea becomes visibly cone-shaped 
and produces a V-shaped deformation of the lower lid when the eye looks 
downward (Munson’s sign). Anterior stromal scars may develop due to 
continuous protrusion of the cornea, especially among patients who wear contact 
lenses. In some cases, breaks in Descemet’s membrane temporarily disrupt the 
cornea’s ability to regulate its hydration and fluid uptake by the overlying stroma 
results in acute vision loss and pain (corneal hydrops). This usually resolves on 
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its own after a few days once the membrane regenerates and normal osmotic 
balance can be restored. 44,45 
 
Diagnosis 
 The most sensitive methods for confirming a diagnosis of KC are 
computerized corneal topography and optical coherence tomography (OCT). The 
former exploits the principles of Placido disc and Scheimpflug imaging to 
precisely map curvature of the corneal surface, revealing steepening of the 
inferior cornea, irregular astigmatism, and other tell-tales. Anterior segment OCT 
(e.g. Pentacam, as illustrated by Figure 5), provides imagery of the cornea in 
cross-section, with measurement of corneal curvature and steepness as well as 
thickness at all locations. 46 
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Figure 5: Example of Pentacam readings from a patient with keratoconus. Top 
left shows the corneal curvature, with inferior steepening. Bottom left shows the 
corneal thickness, with central thinning. 44 
 
The Ocular Response Analyzer (Reichert) is a relatively new method for 
measuring the biomechanical properties of the cornea in vivo, although current 
metrics show significant overlap between normal and KC corneas, causing 
question as to the method’s precision in distinguishing the two for definitive 
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diagnosis. Confocal and specular microscopy can be employed to assess 
changes within the corneal sublayers which often occur with KC, but are not 
specific to KC. These include irregularity of stromal keratocytes, pleomorphism 
and polymegathism of endothelial cells, and epithelial cell abnormalities. 46 
 
Etiology/ Risk Factors 
 Although development of KC involves complex interactions between 
environmental and genetic factors, their relative contributions are currently 
unknown. Recognized environmental influences include contact lens wear and 
chronic eye rubbing (usually associated with general atopy or a more specific 
allergic eye disease). Processes such as inflammation, degeneration, and 
scarring inflict damage to corneal tissue; however, as is the case in many 
complex diseases, it is extremely challenging to distinguish primary disease 
mechanisms from secondary effects, or determine which elements are simply 
associative. Efforts at understanding the pathogenesis of KC are further 
confounded by the fact that most research has been focused on advanced 
presentations of the disease, wherein the origins of the observed pathologies are 
too distant to be traced retrospectively to distinguish individual pathways from 
one another. The diversity and abundance of factors that can lead to corneal 
ectasia such as that seen in KC makes it seem unlikely that there exists a single 
pathway by which the disease manifests, and more likely that the clinical 
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appearance of KC is a common end of many different pathways, either 
independently converging or simultaneously compounding. Despite these 
complications, comparison of normal and KC tissue with regards to protein 
composition, structure, biomechanics, and genetics, reveals key differences 
which inform current theories about underlying disease mechanisms and have 
provided the starting points for development of treatment strategies such as 
photodynamic CXL.   
 
 KC cornea demonstrates a difference in expression of several corneal 
proteins relative to normal cornea including up-regulation of decorin and 
keratocan proteoglycans, and differential expression of several enzymes involved 
in tissue remodeling. 47 Notably, there is a significant reduction in LOX and 
collagen transcript levels in KC corneal epithelia, and LOX activity isolated from 
the tear film correlated with disease severity. 48 KC corneas demonstrate 
alterations in stromal collagen distribution and orientation, also in proportion to 
the severity of the case. This is consistent with a mechanism of KC progression 
involving inter-fibrillar or inter-lamellar slippage resulting in redistribution of 
collagen within the tissue. 49 This mechanism is further supported by the above-
discussed observations of reduced lamellar interlacing within the anterior central 
KC stroma, and fewer lamellar insertions into Bowman’s layer. 36 X-ray diffraction 
studies have shown that the normal orthogonal orientation of deeper stromal 
lamellae 40 is drastically altered in the apical region of advanced KC, and that the 
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pattern of redistribution of collagen away from the apical cone is variable 
between individual cases. 37,49  
 
 Although the majority of KC cases are sporadic, and the hereditary pattern 
is neither prominent nor predictable, the prevalence of KC in first degree relatives 
of index cases is significantly higher than that of the general population. 50 There 
is a high concordance among monozygotic twins, including a high degree of 
phenotypic similarity. 51 KC has also been associated with a range of hereditary 
conditions including Down’s syndrome, Lever congenital amaurosis, atopy, and 
Marfan’s syndrome. However, the causative genetic variants of these conditions 
have not been consistently identified in isolated cases of KC. Although many 
candidate genes have been identified, no contributing gene has yet been found. 
Regardless, genetic analysis of global scale is beginning to elucidate affected 
pathways, and genetic susceptibility is agreed upon as a key factor in the 
pathogenesis of KC. 52  
Reconciling the interplay of genetic and environmental influences in the 
etiology of KC is still the realm of speculation. However, these findings may help 
to explain how an environmental insult such as chronic eye rubbing can have 
such a damaging impact in KC but not normal corneas: a collagen suprastructure 
which is genetically predisposed to weakness and slippage is made vulnerable to 
mechanical stress from the environment. This is the so-called “second hit” 
hypothesis, that genetic factors may make an individual more prone, but 
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environmental factors are necessary to initiate or accelerate the progression of 
KC.  
 
Review of Major Treatments Prior to CXL 
For decades, the management of KC has been focused on mitigating 
symptoms, mainly improving vision with corrective lenses. There is no cure, and 
before collagen cross-linking, there was no way to stop progression, thus corneal 
transplant was often inevitable. Many of the treatments employed prior to CXL’s 
FDA approval (2016) are still relied upon for patients with mild cases or those 
who have contraindications which preclude them from CXL treatment. These 
modalities are effective in improving visual acuity, but they do not prevent it from 
getting worse as KC progresses. The next section provides a brief background 
on some of the more commonly employed options.  
  
Contact Lenses 
The only non-interventional options are corrective lenses. Spectacles are 
only effective at correcting regular astigmatism and very low amounts of irregular 
astigmatism, thus only sufficing in very early cases of KC. Once the cylindrical 
power (a measure of astigmatism) increases beyond 4.0 diopters, contact lenses 
become necessary. These are usually rigid gas permeable lenses as opposed to 
normal soft contact lenses. Rigid lenses can flatten the cone of the KC cornea, 
giving it a more regular shape, whereas soft lenses tend to conform to the 
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irregular shape of the KC cornea, thus diminishing their corrective effect. Several 
varieties of custom contact lenses have been employed, each aimed at 
accommodating different phenotypes of KC cornea. 53 
 
Surgery 
 Interventional options include various types of keratoplasty (corneal 
surgery) as well as insertion of intracorneal rings (ICRs).  
Conductive keratoplasty uses low-energy radiofrequency current to apply 
heat to the flat axis of the peripheral KC cornea. The heat causes collagen in the 
peripheral cornea to shrink, which increases the steepness on that access at the 
central cornea, thereby reducing astigmatism. It is only a temporary fix, as re-
steepening usually occurs, and the results are not always predictable due to 
variable tissue response to thermal treatment. Thus, conductive keratoplasty is 
not preferred. Penetrating keratoplasty (corneal transplant) is inevitable in the 10-
25% of KC patients for whom progression has passed the point of possible visual 
rehabilitation. Because corneal tissue is avascular, tissue match between donor 
and host is relatively easy, and risk of complications is relatively low. However, 
reported complications include allograft rejection, more astigmatism, endothelial 
cell damage, and the side effects that come with long-term use of topical 
corticosteroids (a requirement after transplantation). This procedure is indicated 
for advanced progressive disease with significant corneal scarring. Because 
rejection episodes are usually endothelial in origin, a recent trend is to remove 
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only the diseased part of the cornea, sparing the healthy endothelial cells 
(lamellar keratoplasty). This technique has been shown to have fewer post-
operative complications; however, full-thickness penetrating keratoplasty tends to 
have slightly better outcomes in terms of final best corrected visual acuity 
(BCVA).  
 
Intracorneal rings are made from polymethylmethacrylate, a biocompatible 
plastic otherwise known as acrylic. Insertion into the peripheral cornea to 
increase its thickness to achieve a flattening of the central cornea, as predicted 
by the Barraquer thickness law: adding material to the peripheral cornea flattens 
the central cornea whereas removing material from the periphery steepens it. 
These segments also provide a biomechanical reinforcement for the thin ectatic 
cornea. The radial positioning of the insert, its diameter and thickness, as well as 
its distance from the corneal apex are variables by which the desired effect can 
be achieved. ICRs are contraindicated in immunocompromised patients, or those 
with habitual eye rubbing. There is no improvement of visual disturbance caused 
by corneal scarring, and the procedure cannot be performed on corneas of 
thickness < 350 micrometers at the thinnest location, in which case lamellar 
keratoplasty would be indicated. This procedure is also more complex, and the 
traditional mechanical technique of creating the tunnel into which the segment is 
inserted is very much an art. Minor imperfections or mistakes made by a less-
experienced surgeon are usually to blame for undesired outcomes or rare 
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complications, and advances in corneal tomography and the increasing use of 
femtosecond lasers for tunnel creation have reduced these. Even if insertion is 
perfect, patients may be left with aberrations and night glare, although these 
usually diminish gradually after 6 months for unknown reasons (possibly neural 
compensation/ plasticity in the visual cortex). There are other treatment 
modalities for KC including laser surgery, placement of a variety of intraocular 
lenses, partial or crescent-shaped transplants, and combinations of these. 
However, the only treatment which can actually halt the progression of KC is 
riboflavin/UVA-induced corneal collagen cross-linking (CXL). 53 
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CXL 
 Corneal collagen cross-linking (CXL) increases the stiffness and stability 
of the corneal stroma with the aim of arresting KC progression and avoiding 
corneal transplant (keratoplasty). This novel approach uses riboflavin as a 
photosensitizer, excitable by ultraviolet-A (UVA) irradiation, to induce inter-
collagen fiber bonding in the otherwise cross-link deficient KC cornea. The 
general outcome is strengthening, thickening, and flattening of the anterior 
corneal stroma. Although some cases do show a slight improvement in visual 
acuity, the major objective is to simply prevent it from getting worse. This is a 
revolution in the treatment paradigm for KC, especially for young patients, 
potentially saving them from a lifetime of declining vision, not to mention the cost 
and complications associated with corneal transplantation. 
 
As discussed previously, collagen molecules are enzymatically cross-
linked in a mechanism dependent on post-translational modifications by lysyl 
oxidase. Lysyl oxidase malfunction is implicated in KC, either due to a gene 
defect or some other factor causing deficiency or ineffectiveness of the enzyme, 
thus resulting in fewer cross-links and weak, slippage-prone tissue. Non-
enzymatic cross-linking by sugar aldehydes (AGEs) also occurs and increases 
with age. Cross-links can be induced for therapeutic purposes with chemical 
agents such as glutaraldehyde or formaldehyde, but these cannot be targeted. 
On the other hand, the photopolymerization effect of photo-oxidative reactions 
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induced by a photosensitizer and ionizing radiation can be localized to only the 
tissue exposed to the radiation. Riboflavin and ultraviolet-A (RFUVA) has 
emerged as the preferred method for therapeutic photopolymerization because 
its effect can be localized, riboflavin is nontoxic and bioavailable, a short duration 
of therapy is sufficient, and the transparency of the cornea is left unaltered. Here, 
“CXL” will refer specifically to RFUVA. 
 
Figure 6: The molecular structure of riboflavin. 54 
   
The exact mechanisms of the reactions induced by CXL are still being 
elucidated. Current research suggests that CXL exerts its effect at the molecular 
level, as opposed to the lamellar level. 55 Riboflavin’s charged nature makes it 
hydrophilic and thus permeable within the corneal stroma (see Figure 6 above). 
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Cross-links form between collagen molecules (involving AGEs), 56 between 
proteoglycan core proteins, and between PG core proteins and collagens. 57 It is 
the carbonyl groups rather than amine groups of the proteins that participate, and 
singlet oxygen plays a major role. 58  
 
Energetically, CXL is comparable to photosynthesis – radiation energy is 
transformed into chemical energy with the aid of a pigment. The transfer of 
energy into chemical bonds means that very little heat is produced. In CXL, there 
is a maximum temperature increase of 2-3 °C, an amount not sufficient to cause 
the observed changes, nor to cause tissue damage. 59 Instead, riboflavin 
molecules absorb light energy and move from a ground state to an electronically 
excited state (singlet riboflavin).  
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Figure 7: Riboflavin’s absorption spectrum. 60 
 
Riboflavin’s absorption spectrum dictates the wavelength(s) of light at 
which it absorbs the most energy. As shown by Figure 7, this spectrum has a 
peak that matches the wavelength of ultraviolet-A (365 nm), thus making 
riboflavin/UVA an effective pair for photoexcitation. Excited singlet riboflavin 
rapidly converts to triplet riboflavin, which then participates in one of two reaction 
processes. In the type II process, triplet riboflavin interacts with oxygen to create 
singlet oxygen radicals which then oxidize the carbonyl groups of amino acids in 
collagen (especially histidine), to create covalent linkages. However, if oxygen is 
depleted by UVA, the type I process dominates, whereby excited riboflavin 
triplets react directly with their substrates in collagen via hydrogen or electron 
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transfer reactions. 61 Thus photo-oxidation of susceptible amino acids is the 
primary process, with subsequent covalent cross-linking occurring via secondary, 
light-independent reactions. Figure 8 provides a conceptual flowchart for the 
interactions of substrate and riboflavin in the primary processes (Type I and Type 
II). 
 
Figure 8: Photochemical reaction pathways of RFUVA CXL. 61–63 
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There are five photo-oxidizable amino acids with varying reactivity to 
singlet oxygen and varying abundance in corneal collagen: tryptophan, tyrosine, 
cysteine, methionine, and histidine. While cysteine and tryptophan are highly 
reactive, they are nearly nonexistent in corneal collagen. Methionine, despite 
being oxidizable, is not known to participate in the formation of cross-links. 
Tyrosine can participate in cross-linking by a type I process but is therefore 
inhibited by the presence of oxygen which favors the type II pathway. 64,65 Thus, 
histidine appears to be the major amino acid player in protein-protein CXL 
reactions. This is supported by the finding that proteins lacking histidine do not 
form cross-links in the presence of singlet oxygen. 66 
 
Effects 
 With current technology, RFUVA-induced cross-links in the cornea cannot 
be visualized with labeling methods or microscopic techniques. However, there 
are measurable changes in certain properties of the tissue which can be used as 
indirect indication of cross-linking having occurred, and to what extent. Note, 
most of these studies have been conducted on ex vivo non-human corneas, but 
the difference in tissue between species in terms of composition and organization 
is negligible. Stress-strain experiments indicate that cross-linked tissue is stiffer 
and less elastic, and that this firming effect is sufficient to compensate for the 
decreased stability seen in KC. 67–69 There is also a decrease in the tissue’s 
tendency to swell, 70 and a 4.5% increase in the diameter of collagen fibers in the 
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anterior stroma. 71 Recent studies have shown a significant increase of 
proteolytic enzymes in the tear films of KC patients (e.g. MMP), likely contributing 
to the degradative progression of the disease. 72 However, CXL increases the 
cornea’s resistance to enzymatic degradation, making it less susceptible to 
thinning but also lengthening the collagen turnover time. 73 Finally, gel 
electrophoresis reveals the creation of molecular aggregates of greater molecular 
weight. These varied in size, and included an especially stable polymer not found 
in normal cornea. 74 This supports the findings that CXL induces several different 
types of cross-links between numerous substrate pairs, as opposed to one 
specific type by a single mechanism.  
  
 CXL does not exert its effect uniformly through the entire thickness of the 
cornea, but only where the riboflavin/UVA interaction takes place. The 
concentration of riboflavin decreases linearly with increased stromal depth, 
according to its diffusion gradient. 75 Additionally, the intensity of UVA irradiation 
decreases exponentially with depth, in proportion to the concentration of the 
attenuating riboflavin (Beer-Lambert law). 76 Thus, there is a much greater 
interaction of these two components nearer to the corneal surface. In fact, 65% 
of the light energy is absorbed (and directed into the formation of cross-links) in 
the first 200 μm of anterior stroma. 68,73 This Beer-Lambert effect has important 
ramifications for treatment optimization, to be discussed later.   
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 The relevant clinical effects of CXL are focused on halting disease 
progression as measured by four major criteria pre- and post-operation: 
topography, visual acuity, refraction/ astigmatism, and central corneal thickness. 
A meta-analysis of 49 human studies demonstrates statistically significant 
improvements in all outcomes at 1 year post-operation. Maximum keratometry 
values (a topographic measure of corneal steepness) were reduced by about 1 
diopter. Best corrected visual acuity (BCVA) improved somewhat, although 
uncorrected acuity showed no improvement. Improvements in astigmatism were 
an average change of -0.7 diopters at 1 year, and -0.5 diopters at 24 months. 
Finally, there was a reported average reduction of -14.4 μm in central corneal 
thickness. 77  
Cellular changes following CXL have been considered. The removed 
epithelium is restored in 4 days following treatment, and no damage to limbal 
stem cells, nor abnormalities in cell proliferation. Within the stroma, wound 
healing mechanisms are triggered, including keratocyte apoptosis. 3-6 months 
after CXL, new keratocytes migrate from the periphery to the center concurrent 
with an increased density of the ECM in the anterior stroma. The difference in 
density creates a difference in reflectivity upon confocal microscopy termed the 
“late demarcation line,” providing a useful clinical tool for confirming CXL impact. 
78 These structural changes, coupled with the synthesis of new collagen by 
migrating keratocytes, further support the long-term stability of CXL’s effect on 
corneal biomechanics. Finally, endothelial cell changes show no significant 
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difference between CXL and untreated eyes. This is because 90% of the UVA 
energy is absorbed in the riboflavin-treated cornea (approximately 400 μm thick). 
Thus, the amount of radiation reaching the endothelial layer is about half (0.18 
mW/cm²)79 the minimum amount needed to cause cellular damage (0.35 
mW/cm²). 80 
 
 Analysis of 24 CXL patients 10 years post-operatively confirms long-term 
efficacy in stabilizing KC corneas, finding significant improvement in BCVA and 
corneal topography measures. Furthermore, although damage to the 
endothelium has historically been the major safety concern in CXL, this analysis 
found no decline in endothelial cell count beyond what would be expected with 
normal aging in untreated eyes. 81 
 
Current Standard Procedure: Avedro’s KXL System 
Following the promising results of initial experiments using photosensitizer 
to generate cross-links in the eye, 82 CXL was first implemented for the treatment 
of keratoconus in 1998. The pilot study, conducted in Dresden, halted 
progression in all 22 patients and had no immediate side effects, 67 paving the 
way for the current clinical treatment which finally gained FDA approval in April of 
2016.  
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The original “Dresden protocol” involved removal of the central 7 mm of 
corneal epithelium followed by administration of 0.1% riboflavin in 20% dextrin 
solution for 5 minutes before, and every 5 minutes during, a 30-minute irradiation 
period with 370 nm wavelength UVA at 3.0 mW/cm2 intensity. The differences 
between this and the current treatment protocol are as follows: Avedro’s 
Photrexa Viscous riboflavin solution has a concentration of 0.146% riboflavin 
(also in 20% dextrin). Photrexa Viscous is applied every 2 minutes for 30 minutes 
before, and every 2 minutes during, the 30-minute irradiation period. Before 
beginning irradiation, thorough absorption of riboflavin through the entire depth of 
the cornea is confirmed by presence of flare in the anterior chamber upon slit-
lamp examination (Tyndall effect).  Because Photrexa Viscous is hypertonic, it 
draws water out of the cornea, reducing its thickness. If the cornea is measured 
to be less than 400 μm thick (by ultrasound pachymetry) after the initial “soak” 
period, 1-2 drops of a different solution (Photrexa) are applied every 5-10 
seconds to swell the cornea back to above threshold. Photrexa has the same 
concentration of riboflavin, but without the dextrin, making it hypotonic. A 
minimum corneal thickness of 400 μm is required to ensure that the energy 
reaching the endothelium is below the damage threshold.  
 
 The FDA lists no contraindications. The most common ocular adverse 
reactions observed during clinical trials were corneal opacity (haze), punctate 
keratitis, corneal striae, corneal epithelium defect, eye pain, and reduced visual 
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acuity (blurry vision). The majority of adverse events resolved during the first 
month; however, patients are counseled that vision can take up to 1 year to fully 
stabilize. 54 
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MAJOR PROPOSED PROCEDURAL MODIFICATIONS 
Broadly speaking, the major parameters that can be modified are how the 
light energy is delivered (and how much), and the composition of the riboflavin-
containing solution and how it is delivered. The major goal of treatment 
optimization is to minimize the total treatment time, while maximizing clinical 
effect and patient comfort. Shorter treatments are more comfortable for the 
patient, allow a higher throughput for the practitioner, and present a theoretically 
lower risk of infection.  
 
Irradiance 
According to the Bunsen-Roscoe law, all photochemical reaction 
mechanisms depend only on the total absorbed energy and are statistically 
independent of the two factors that determine total absorbed energy – the radiant 
intensity, and exposure time. 83 This would predict that the extent of 
photooxidative cross-linking that occurs with CXL will be the same given that the 
total energy delivered is the same. However, it is known that many 
photochemical reactions (e.g. film photography) demonstrate Bunsen-Roscoe 
validity only within a certain range, and it is not yet known how large this range is 
for RFUVA CXL. This led to exploration of the equivalence of various increased 
light intensities and proportionally decreased irradiation durations in regards to 
efficacy.  
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 Stress-strain experiments on porcine corneas have shown equivalence in 
stiffening effect between standard CXL (S-CXL) and an accelerated CXL (A-CXL) 
using 10 mW/cm2 for 9 minutes. 84 Follow up experiments saw an equivalent 
stiffness increase with increasing intensities (and corresponding decreased 
durations), but only up to approximately 45 mW/cm2, beyond which there was a 
sudden drop to no significant difference from controls. 85 Neither study addressed 
the safety of higher intensities for humans. Shetty et al recently compared 4 
patient groups with equivalent total delivered energy: 3 mW/cm2 for 30 minutes 
(Group 1, S-CXL), 9 mW/cm2 for 10 minutes (Group 2), 18 mW/cm2 for 5 minutes 
(Group 3), and 33 mW/cm2 for 3 minutes (Group 4). Across the four groups, the 
clinical CXL effect declined in proportion to the increase in intensity. While 
groups 1 and 2 showed the typical flattening effect evidenced by reduced 
keratometry values, groups 3 and 4 showed stabilization but not reduction. 
Furthermore, demarcation lines, which denote the area of keratocyte apoptosis 
caused by RF penetration and thus provide an indirect measure of CXL effect, 
were less and less defined with increasing intensities. Disease progression was 
observed only in groups 3 and 4. 86 Furthermore, although this study found no 
significant difference in endothelial cell count, other research has indicated 
transient changes in cell density and morphology following A-CXL at 18 mW/cm2 
for 5 minutes. 87 While the endothelial cells do recover safely after an average of 
6 months, this is clear evidence of endothelial effects following A-CXL, the 
repercussions of which need further exploration.  
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  The apparent failure of the Bunsen-Roscoe law in the case of A-CXL is 
likely because the treatment effect is not achieved by a single photochemical 
reaction but by multiple different pathways and likely including other downstream 
effects due to long term cellular changes which have yet to be elucidated. One 
explanation is that higher intensity radiation induces faster consumption of 
oxygen and therefore reduces the efficiency of the oxygen-dependent (type II) 
reactions. The importance of oxygen availability is demonstrated by data showing 
a complete lack of CXL effects when performed in anaerobic conditions. 61  
 
 Because photochemically generated reactive oxygen species (ROS) are 
needed to react with proteoglycan core proteins and collagen to induce cross-
linking, more protein oxidation should result in more cross-linking. Thus, the 
power of different CXL modalities can be assessed by quantifying advanced 
oxidation protein products (AOPPs), a measure of protein oxidation. One method 
of increasing oxygen availability during CXL is to use pulses of light as opposed 
to a continuous exposure. Theoretically, pulsed light accelerated CXL (PLA-CXL) 
allows stromal oxygen concentrations to be replenished, enabling delivery of an 
equivalent dose of energy in less time without sacrificing photochemical 
efficiency, thus side-stepping the disadvantage of continuous exposure A-CXL. 
Supportive of this theory, recent research measured more AOPPs after PLA-CXL 
than both S-CXL and A-CXL. 88 Although it is assumed that higher levels of 
 47 
 
AOPPs will result in greater cross-linking, further studies directly equating AOPP 
levels with clinical effect are needed for confirmation.  
 
Modeling 
Mathematical models, scaled to experimental results, have been 
formulated to predict the extent and distribution of stromal stiffness increase as a 
function of variable treatment parameters (riboflavin concentration, radiation 
intensity, time). Fick’s second law of diffusion, the Lambert-Beer law of light 
absorption, and reaction rate equations are used to predict the rate of cross-
linking (polymerization rate). Experimental results for stiffness increase are 
correlated with the simulated polymerization rate increase. 62,63 Recall that 
riboflavin absorbs UVA and induces polymerization, and its concentration decays 
linearly as a function of corneal depth. Meanwhile, the intensity of light decays 
exponentially with depth. This is important for predicting not just the total stiffness 
change of the cornea (as has been measured in efficacy experiments to date), 
but also the distribution of that change across its depth. A reduction in riboflavin 
concentration results in deeper light penetrance and a more uniform effect. 
Conversely, increasing the concentration results in more energy being absorbed 
nearer to the corneal surface but declining more precipitously as you move 
deeper, creating a much less uniform effect profile. This is supported by data 
showing shallower demarcation lines with A-CXL (although reports of exact depth 
vary widely between 100-150 um 89 and 294 um 90) as opposed to ~300 um in S-
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CXL. 78 This appears to be a function of total treatment time rather than radiation 
intensity given that pulsed exposures achieve greater demarcation line depths at 
the same intensity. 91 Furthermore, the less uniform the profile, the lower the total 
stiffness increase. One interesting modeled prediction is that, with riboflavin 
concentration held constant at 0.1%, the polymerization rate increases with 
increasing intensities but then saturates at approximately 3.0 mW/cm2. 
Therefore, although the total amount of cross-linking may vary as a function of 
time, the actual rate at which it happens does not get any faster with excessively 
high intensities. This simulation corroborates quite well with the experimental 
data discussed above. Furthermore, it validates the parameters of S-CXL for best 
effect within the constant exposure modality. In fact, this model 62 predicts the 
slightly higher RF concentration of 0.146% for optimal polymerization rate while 
keeping the light penetrance below the endothelial damage threshold.  
 
Riboflavin Delivery 
Other experimental treatment modalities attempt to achieve the same 
clinical effect as S-CXL without removing the epithelium. This reduces post-
operative pain, 92 and allows for faster return to optimal vision. Unfortunately, 
riboflavin diffusion into the stroma is dramatically hindered by the intact 
epithelium, showing a detectable penetration depth of only 20 μm compared to 
400-600 μm when the epithelium is removed. 75 Therefore, various methods have 
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been employed to try to increase RF penetrance without damaging the 
epithelium.  
 
The use of the chemical agent benzalkonium chloride or EDTA to reduce 
epithelial resistance has demonstrated safety but increased corneal stiffness by 
an amount only 1/5th that of S-CXL with epithelial debridement, 93,94 and 
anywhere from 23% 95 to 55% 96 of patients showed continued disease 
progression. One study using a combination of chemical enhancers (gentamicin 
0.3%, EDTA 0.01%, and benzalkonium chloride 0.01%) successfully stabilized 
corneal curvature, but still demonstrated a less-pronounced effect than S-CXL. 97 
Because riboflavin is a charged molecule of small molecular weight, it is a good 
candidate for iontophoresis. Use of iontophoresis with 0.1% hypotonic riboflavin 
and double-enhancement with EDTA and trometamol under accelerated 
irradiation of 10 mW/cm2 for 9 minutes did prevent KC progression up to 1 year 
without endothelial cell count change or reduction in central corneal thickness. 
However, no demarcation line was observed, and the biomechanical effect, 
although greater than typical trans-epithelial modalities, was still inferior to S-
CXL. 98 Some encouraging results were obtained very recently using Vitamin E 
as an enhancer. Disease progression was halted and there was no detectable 
endothelial damage up to 2 years post-operatively. However, only 19 patients 
were studied and a control group to provide comparison to S-CXL was not 
employed. 99   
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CONCLUDING REMARKS 
 There are a few things to keep in mind which the current literature does 
not extensively address.  
 
Regarding the effectiveness of various CXL modalities in compensating 
astigmatism, it is true that a general flattening of the cornea tends to improve 
refractions and reduce astigmatism; however, refractions depend on subjective 
patient responses and are notoriously difficult and variable in KC patients due to 
the multifocal optics of the distorted cornea. Thus, reference to improved 
refractive outcomes are insufficient on their own to indicate treatment efficacy.  
 
Current assessment of endothelial safety focuses on the endothelial cells 
themselves (density, morphology), but evidence is lacking regarding the impact 
of higher UV intensities on the nerves of the endothelial layer (the subbasal 
plexus). If nerve damage here would negatively impact the health of the 
endothelium, the status of the subbasal plexus should be included in 
assessments of safety.  
 
 The delivery of riboflavin solution by the typical drop method introduces 
complications. Because drops disperse upon the eye, the effective concentration 
at the ocular surface is significantly less than the initial concentration of the 
solution. The placement of a Landers vitrectomy silicone ring on the limbus 63,95 
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to maintain a pool of solution over the treatment area will result in more 
consistent penetrance and concentrations within the stroma. Also, the shielding 
effect caused by excess riboflavin at the ocular surface makes actual light 
penetrance (and therefore energy delivery) both lower than expected and also 
variable, depending on the changing thickness of this layer between drops. 
Washing the riboflavin film before irradiation would make treatments more 
consistent/ reproducible, and should also reduce the intensity requirement. 
However, without constant reapplication during irradiation, intrastromal riboflavin 
concentrations will fall, potentially exposing the endothelium to too much 
radiation. The temporal component introduced by this diffusion-dependent 
intrastromal de-shielding would need further exploration.  
 
 Finally, theoretical models are useful but are not yet comprehensive. For 
example, current models only account for the energy delivered to the reaction 
system via light absorbance, without consideration of light scatter. Furthermore, 
more depth-dependent analyses of CXL effect are needed to precisely model the 
uniformity and distribution of cross-linking.  
 
Summary 
KXL is an effective and safe treatment for KC. Although the exact 
mechanisms are still not fully understood, there appear to be certain 
requirements and limitations for any RFUVA-type CXL paradigm: oxygen 
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availability is an important factor, the Bunsen-Roscoe law does not neatly apply 
to CXL reactions, epithelium removal is still superior to trans-epithelial modalities 
(although some of the methods for facilitating stromal riboflavin delivery may 
prove helpful for shortening the pre-soak period), and the optimal constant-
exposure irradiation is likely no greater than 18 mW/cm2 intensity for a period of 5 
minutes (maintaining the total energy delivered at 5.4 J/cm2), although PLA-CXL 
may prove to have a different optimum.  
 
With a complete understanding of various treatment parameters’ specific 
impact on outcomes, and therefore more precise models, it seems likely that 
physicians will soon be able to tailor each treatment to be specific to the 
individual’s unique disease profile (severity, phenotypic presentation, corneal 
thickness, etc.). In the meantime, the established requirements and limitations for 
producing clinically effective CXL should inform research focus. By current 
understanding, PLA-CXL, at intensities up to 18 mw/cm2, seems to have the 
greatest potential for decreasing treatment times while maintaining optimal 
clinical effect.  
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